Although pre-clinical studies have produced diverging evidence on the effects of IL6 and the utility of its in-tumour levels as a marker remains unclear [123,124,125,126], the role of circulating serum IL6 levels as a negative prognosticator in BC has been well established [79,92]. This evidence concerns the gene IL6 and breast cancer.